WHO Advises Clinical Trials for Bundibugyo Virus Treatments and Vaccines
The Story
The World Health Organization convened expert advisory groups to assess candidate treatments and vaccines for the current outbreak of Ebola disease caused by the Bundibugyo virus in the Democratic Republic of the Congo, with cases also reported in Uganda. No licensed therapeutics or vaccines are specifically approved for Bundibugyo virus disease (BVD). The WHO advisory groups recommended that all products considered be used exclusively within clinical trials to generate robust data while ensuring safe, ethical, and effective research. WHO is working with the governments of the Democratic Republic of the Congo and Uganda to facilitate the implementation of research evaluations. The experts prioritized three candidate therapeutics for treatment evaluation: the monoclonal antibodies MBP134 and Maftivimab, as well as the antiviral remdesivir. For prevention, the oral antiviral obeldesivir was determined a priority candidate for post-exposure prophylaxis among contacts, though this depends on effective contact tracing. Two candidate vaccines were identified: a single-dose rVSV Bundibugyo vaccine and a ChAdOx1 Bundibugyo vaccine, with different timelines for clinical trial readiness.
Key Facts
- No licensed therapeutics or vaccines are specifically approved for preventing or treating Bundibugyo virus disease (BVD).
- WHO advisory groups recommended prioritizing three candidate therapeutics for evaluation in clinical trials among confirmed BVD cases: MBP134, Maftivimab, and remdesivir.
- For post-exposure prophylaxis, the oral antiviral obeldesivir was identified as a priority candidate.
- The single-dose rVSV Bundibugyo vaccine (IAVI) will likely require 7–9 months before ready for clinical trial assessment.
- The ChAdOx1 Bundibugyo vaccine (Oxford/Serum Institute of India) could become available within 2–3 months but requires additional animal data.
- The licensed Zaire ebolavirus vaccine Ervebo should not be used outside carefully designed clinical trials for BVD, as evidence on cross-protection remains limited.
Conflicting Reports
No conflicting reports identified across sources.
Still Unclear
- STAT News reports that the Trump administration confirmed any Americans who contract Ebola will be evacuated to Europe rather than the United States for treatment. (Single-source claim)
- STAT News reports that a Kenyan court put a hold on the U.S. plan to build a quarantine facility in Kenya until petitions can be heard next week. (Single-source claim)
- The exact number of confirmed cases in DRC and Uganda is not provided by either source.
Misconceptions
No widespread misconceptions addressed in the sources.
Key Figures
- World Health Organization (WHO)
- Strategic Advisory Group of Experts on Immunization (SAGE)
- International AIDS Vaccine Initiative (IAVI)
- Oxford University / Serum Institute of India
Sources: World Health Organization, statnews.com
